Relationship of ventricular assist device support duration with pediatric heart transplant outcomes.

dc.contributor.author

Butto, Arene

dc.contributor.author

Mao, Chad Y

dc.contributor.author

Wright, Lydia

dc.contributor.author

Wetzel, Martha

dc.contributor.author

Kelleman, Michael S

dc.contributor.author

Carboni, Michael P

dc.contributor.author

Dipchand, Anne I

dc.contributor.author

Knecht, Kenneth R

dc.contributor.author

Reinhardt, Zdenka

dc.contributor.author

Sparks, Joshua D

dc.contributor.author

Villa, Chet

dc.contributor.author

Mahle, William T

dc.date.accessioned

2022-02-01T17:15:28Z

dc.date.available

2022-02-01T17:15:28Z

dc.date.issued

2022-01

dc.date.updated

2022-02-01T17:15:27Z

dc.description.abstract

Background

There is wide variability in the timing of heart transplant (HTx) after pediatric VAD implant. While some centers wait months before listing for HTx, others accept donor heart offers within days of VAD surgery. We sought to determine if HTx within 30 days versus ≥ 30 after VAD impacts post-HTx outcomes.

Methods

Children on VAD pre-HTx were extracted from the Pediatric Heart Transplant Study database. The primary endpoints were post-HTx length of hospital stay (LOS) and one-year survival. Confounding was addressed by propensity score weighting using inverse probability of treatment. Propensity scores were calculated based on age, blood type, primary cardiac diagnosis, decade, VAD type, and allosensitization status.

Results

A total of 1064 children underwent VAD prior to HTx between 2000 to 2018. Most underwent HTx ≥ 30 days post-VAD (70%). Infants made up 22% of both groups. Patients ≥ 12 years old were 42% of the < 30 days group and children 1 to 11 years comprised 47% of the ≥ 30 days group (p < 0.001). There was no difference in the prevalence of congenital heart disease vs. cardiomyopathy (p = 0.8) or high allosensitization status (p = 0.9) between groups. Post-HTx LOS was similar between groups (p = 0.11). One-year survival was lower in the < 30 days group (adjusted mortality HR 1.76, 95% CI 1.11-2.78, p = 0.016).

Conclusions

A longer duration of VAD support prior to HTx is associated with a one-year survival benefit in children, although questions of patient complexity, post-VAD complications and the impact on causality remain. Additional studies using linked databases to understand these factors will be needed to fully assess the optimal timing for post-VAD HTx.
dc.identifier

S1053-2498(21)02521-3

dc.identifier.issn

1053-2498

dc.identifier.issn

1557-3117

dc.identifier.uri

https://hdl.handle.net/10161/24311

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation

dc.relation.isversionof

10.1016/j.healun.2021.09.011

dc.subject

PHTS

dc.subject

congenital heart disease

dc.subject

pediatric VAD

dc.subject

pediatric cardiomyopathy

dc.subject

pediatric heart transplant

dc.subject

pediatric heart transplant outcomes

dc.title

Relationship of ventricular assist device support duration with pediatric heart transplant outcomes.

dc.type

Journal article

duke.contributor.orcid

Carboni, Michael P|0000-0002-9875-7276

pubs.begin-page

61

pubs.end-page

69

pubs.issue

1

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Pediatrics

pubs.organisational-group

Pediatrics, Cardiology

pubs.publication-status

Published

pubs.volume

41

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PIIS1053249821025213.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Published version